Casdin Capital’s Rapport Therapeutics RAPP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.72M Buy
+200,000
New +$8.63M 0.29% 36

Other funds holding RAPP

Casdin Capital's RAPP Position: Q3 2026 in Review

Casdin Capital opened a new position in Rapport Therapeutics (RAPP) in Q3 2026: 200,000 shares worth $6.72M. The stake represents 0.29% of the portfolio and ranks #36 among its holdings.

169 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.

  • Casdin Capital held 200,000 shares of Rapport Therapeutics worth $6.72M as of Q3 2026.
  • Rapport Therapeutics was a new Casdin Capital position in Q3 2026.
  • Rapport Therapeutics made up 0.29% of Casdin Capital's portfolio in Q3 2026, its #36 holding.
  • 169 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.

Based on Casdin Capital's 13F filing for Q3 2026, filed 16 Nov 2026.